n-(4-(n-((2,4-diaminofuro(2,3-d)pyrimidin-5-yl)methyl)amino)benzoyl)glutamic acid has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 1 studies
*Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Devraj, R; Gangjee, A; Kisliuk, RL; McGuire, JJ | 1 |
1 other study(ies) available for n-(4-(n-((2,4-diaminofuro(2,3-d)pyrimidin-5-yl)methyl)amino)benzoyl)glutamic acid and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
Topics: Antineoplastic Agents; Cell Division; Folic Acid; Folic Acid Antagonists; Humans; Hypoxanthine; Hypoxanthines; Kinetics; Lacticaseibacillus casei; Leucovorin; Methotrexate; Molecular Structure; Peptide Synthases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recombinant Proteins; Structure-Activity Relationship; Thymidine; Thymidylate Synthase; Tumor Cells, Cultured | 1995 |